Abstract
Introduction and ObjectivesDupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL) 4 and IL-13, key and central drivers of type 2 (T2) inflammation, and demonstrated...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have